Finerenone and Empagliflozin in Type 2 Diabetes

Cardiovascular disease and chronic kidney disease remain the leading causes of morbidity and mortality in patients with type 2 diabetes, even when conventional risk factors are well managed. Two drug classes have emerged over the past decade that reduce these risks through mechanisms that are largely independent of glucose lowering effect: sodium–glucose cotransporter 2 inhibitors and nonsteroidal mineralocorticoid receptor antagonists. Empagliflozin demonstrated reductions in cardiovascular mortality, heart failure hospitalization, and kidney disease progression in the EMPA-REG OUTCOME trial and was subsequently shown to benefit patients with heart failure across the ejection fraction spectrum in the EMPEROR trials. Finerenone, the first nonsteroidal mineralocorticoid receptor antagonist with phase III cardiorenal outcome data, reduced both cardiovascular and kidney composite endpoints in the FIDELIO-DKD and FIGARO-DKD trials, effects that were confirmed and strengthened in the pooled FIDELITY analysis of over 13,000 patients. These 2 agents target distinct pathophysiological pathways. Sodium–glucose cotransporter 2 inhibition acts primarily through hemodynamic and tubuloglomerular mechanisms, whereas finerenone addresses mineralocorticoid receptor driven inflammation and fibrosis in cardiac and renal tissue. The CONFIDENCE trial, published in 2025, was the first prospective study to test their combination; finerenone plus empagliflozin reduced urinary albumin.